Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia - Overview
Hyperphosphatemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperphosphatemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperphosphatemia - Companies Involved in Therapeutics Development
3SBio Inc
Ardelyx Inc
Chi Nuokang Bio-Pharmaceutical Inc
Chugai Pharmaceutical Co Ltd
Citragen Pharmaceuticals Inc
J-Pharma Co Ltd
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
Hyperphosphatemia - Drug Profiles
CGN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colestilan chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EOS-789 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanthanum polystyrene sulfote - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Hyperphosphatemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tepanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNI-494 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperphosphatemia - Dormant Projects
Hyperphosphatemia - Discontinued Products
Hyperphosphatemia - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: Ardelyx announces positive second data alysis from ongoing NORMALIZE phase 4 study evaluating Tepanor in CKD patients on dialysis
Dec 04, 2019: Ardelyx reports positive data from tepanor’s Phase III CKD trial
Nov 06, 2019: Ardelyx announces presentation at Kidney Week 2019
Oct 15, 2019: Akebia files lawsuit against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia for its Iron Deficiency Anemia Indication and imposing a prior authorization requirement for its Hyperphosphatemia indication
Sep 03, 2019: Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tepanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment
Mar 07, 2019: Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tepanor for the Treatment of Hyperphosphatemia in the Jourl of the American Society of Nephrology
Feb 07, 2019: Ardelyx collaboration partner, Kyowa Hakko Kirin, announces initiation of a phase 2 clinical study of Tepanor for Hyperphosphatemia patients on dialysis in Japan
Oct 26, 2018: Ardelyx presents new preclinical data demonstrating synergy between Tepanor and Sevelamer when dosed in combition for elevated serum phosphorus
Aug 29, 2018: Ardelyx Announces Science Translatiol Medicine Publication Detailing Tepanor’s Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
May 21, 2018: Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
Nov 21, 2017: Ardelyx Announces Updated Development Path for Tepanor
Apr 18, 2017: Ardelyx To Present Tepanor at Upcoming Spring Medical Meetings
Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tepanor for Hyperphosphatemia in Patients with End-Stage Rel Disease
Jan 06, 2017: Shield Therapeutics Provides Update on PT20
Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Hyperphosphatemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Hyperphosphatemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperphosphatemia - Pipeline by 3SBio Inc, H1 2020
Hyperphosphatemia - Pipeline by Ardelyx Inc, H1 2020
Hyperphosphatemia - Pipeline by China Nuokang Bio-Pharmaceutical Inc, H1 2020
Hyperphosphatemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Hyperphosphatemia - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
Hyperphosphatemia - Pipeline by J-Pharma Co Ltd, H1 2020
Hyperphosphatemia - Pipeline by OPKO Health Inc, H1 2020
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2020
Hyperphosphatemia - Pipeline by Shield Therapeutics Plc, H1 2020
Hyperphosphatemia - Pipeline by Unicycive Therapeutics Inc, H1 2020
Hyperphosphatemia - Pipeline by Vidasym Inc, H1 2020
Hyperphosphatemia - Dormant Projects, H1 2020
Hyperphosphatemia - Discontinued Products, H1 2020